講師資料
Talks：
From A to Z: my first-hand observation of hypoglossal nerve stimulation in USA
舌下神經刺激術在美國的第一手觀察
Name：
蕭凱元（Kai-Yuan Hsiao）
Position：
成大醫院主治醫師
Affiliation：
Division of Oral and Maxillofacial Surgery, Department of Stomatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Email：
Photo：
Research Interests：
Sleep medicine, Sleep dentistry, Oral cancer, Orthognathic surgery, Head and Neck surgery
Selected Publications：
1. Kai-Yuan Hsiao, Tung-Yiu Wong, De-Hui Zhao, Ken-Chung Chen, Jehn-Shyun Huang, Meng-Yen Chen, Enhancing surgical outcomes of posterior iliac bone harvesting through a pivotal modification, Journal of Dental Sciences, 2024; 648-651.
2. Hsiao KY, Gutiérrez Pérez ML, Dos Santos Cé P, Fleury Curado TA. Managing Wound Complications in Hypoglossal Nerve Stimulation: Prevention Strategies and Criteria for Avoiding Device Explantation. Oral Maxillofac Surg Cases. 2025;11(2):100398. doi:10.1016/j.omsc.2025.100398.
3. Kai-Yuan Hsiao, Chiang-Shin Liu, Jing-Jing Fang, Tung-Yiu Wong, Using high condylectomy and optimal symmetry plane based analysis in treatment of unilateral temporomandibular joint osteochondroma: report of three cases and review of literatures. Taiwan Journal of Oral and Maxillofacial Surgery 2022; 33(1):45-58.
Abstract：
Obstructive sleep apnea (OSA) has long been managed through various non-surgical methods—such as weight loss, oropharyngeal muscle training, and use of adjunct devices like CPAP or mandibular advancement devices (MAD)—as well as surgical approaches (phase I/II surgeries to correct airway anatomy, bariatric surgery, etc.). Despite these options, many patients remain inadequately treated or continue to struggle with their condition. This gap has spurred the development of alternative therapies, such as hypoglossal nerve stimulation (HNS). Following the publication of the landmark, multicenter, prospective STAR trial—which demonstrated the promising clinical efficacy of HNS in treating OSA—the first FDA-approved device, Inspire II, was launched in 2014. Over the subsequent decade, nearly 100,000 patients have benefited from this therapy.
What did we learn from these experiences? Can we further stratify responders and non-responders based on specific endotypes or phenotypes? How can complications be effectively prevented or managed? What device modifications and additional device options have emerged in recent years? Furthermore, what insights have surfaced in U.S. clinical observations, peer discussions, and case studies that are less commonly featured in international conferences?
In light of the fact that hypoglossal nerve stimulation is not yet introduced to Taiwan, this presentation serves as a rapid orientation and checklist for clinicians considering adoption of this new medical device. 
2025年會：